Review finds weak evidence on connecting hospitalized alcohol-use patients to follow-up care

A systematic review published September 8 in Annals of Internal Medicine found limited evidence about which hospital-based interventions reliably connect patients with alcohol use disorder to outpatient treatment. The findings highlight an unresolved problem in chronic disease care: helping people continue treatment after an acute hospitalization ends.

Researchers from the University of Colorado Anschutz and Yale University examined 17 studies evaluating 21 interventions. Eight interventions reported improved outpatient follow-up, according to the American College of Physicians’ summary. Results varied substantially, and methodological weaknesses prevented a confident recommendation of a particular approach.

For health systems, the practical issue is consequential. A discharge plan can describe the next stage of care without ensuring that a patient actually reaches it. The review examines that connection, an intermediate step on the path toward sustained recovery and better health.

What the researchers assessed

The review searched five research databases for studies published from January 2000 through February 2025. It included 12 randomized trials involving 1,917 participants, three nonrandomized trials involving 459 participants, and two cohort studies involving 9,974 participants.

Eligible studies compared hospital-based interventions with usual care or another active approach. Most interventions combined several elements, including behavioral support, care coordination, medication management, or social support. This makes it difficult to determine which individual component contributed to a favorable result.

The endpoint was connection to outpatient alcohol treatment after hospitalization. Across randomized trials, reported absolute changes in follow-up ranged from an eight-percentage-point decrease to a 30-percentage-point increase. Those figures describe different studies and interventions; they are not a pooled estimate of what hospitals should expect.

The authors’ abstract identifies high risk of bias and imprecise results as reasons for low confidence in the evidence. The review also excluded publications in languages other than English.

Why promising results remain uncertain

The university’s September 8 announcement reported that 10 of the 12 randomized trials were judged to have a high risk of bias. It also highlighted differences in patient populations and in how researchers measured follow-up.

Together, these limitations complicate comparisons. Counting the interventions with favorable findings does not establish the probability that a discharge program will work elsewhere. Nor does a study showing better appointment attendance automatically demonstrate fewer readmissions, less alcohol-related illness, or longer survival.

The researchers called for better-designed studies that can separate the contributions of behavioral support, care coordination, medications, and peer or family involvement. Such work could help hospitals decide which services deserve resources and how to evaluate their performance.

The connection to long-term health

The National Institute on Alcohol Abuse and Alcoholism describes alcohol use disorder as a chronic condition for which continuing follow-up can be important. Its treatment guidance identifies behavioral therapies, medications, and mutual-support resources as available approaches, with care adapted to individual needs over time.

The institute also describes recovery in terms that extend beyond drinking behavior to physical health, mental health, relationships, and everyday functioning. Those outcomes make continuity of alcohol treatment relevant to healthspan, although this review does not establish a longevity benefit from any discharge intervention.

The distinction matters when interpreting the findings: uncertainty about how best to connect patients with treatment does not invalidate the evidence supporting treatment itself. The new review identifies a weakness in the evidence for delivering continuity of care—a question future trials will need to answer with more consistent methods and meaningful patient outcomes.